^
    Back
    Association details:
    Biomarker:KIT translocation
    Cancer:Melanoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma

    Excerpt:
    A mutation, translocation, or fusion in the KIT gene in the patient's tumor felt to be potentially sensitive to tyrosine kinase inhibition.
    Trial ID:
    NCT02400385